PROJECT 1 - ABSTRACT Age is the single greatest risk factor for Alzheimer's disease (AD); however, the mechanisms linking normative aging and AD remain obscure and have been understudied. The broader goals of this proposal are to (1) understand, at a molecular level, what processes cause cells to become more susceptible to AD as we age and (2) to leverage recent advances in aging research to develop novel therapies that will delay the onset and progression of AD in people. To begin to accomplish these goals, we will utilize the nematode Caenorhabditis elegans as a model system in order to understand the molecular and genetic basis of AD in the context of an aging animal. Specifically, we will develop improved transgenic nematode models for AD-related studies and use these models to accomplish two primary goals. First, we will determine the age-dependent effects of toxic amyloid-beta (A) on global mRNA expression through RNA-Seq analysis. These experiments will be designed and analyzed in a manner to optimally extract meaningful and relevant data that will provide the first comprehensive view of the impact of A on gene expression in the context of normative aging. Second, we will determine the mechanisms by which two important signaling pathways, the hypoxic response and the mechanistic target of rapamycin (mTOR), modulate cellular resistance to A toxicity. We have previously shown that both of these pathways regulate both normative aging and resistance to A in C. elegans. These studies are likely to provide novel insights into the relationship between normative aging and AD, as well as novel therapeutic targets to attenuate the onset and progression of AD in people.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005136-33
Application #
9088286
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
33
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Turk, Katherine W; Flanagan, Margaret E; Josephson, Samuel et al. (2018) Psychosis in Spinocerebellar Ataxias: a Case Series and Study of Tyrosine Hydroxylase in Substantia Nigra. Cerebellum 17:143-151
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Bharadwaj, Rajnish; Cimino, Patrick J; Flanagan, Margaret E et al. (2018) Application of the condensed protocol for the NIA-AA guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice. Histopathology 72:433-440
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Tulloch, Jessica; Leong, Lesley; Chen, Sunny et al. (2018) APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement 14:889-894
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 753 publications